Evidence of Clinical Activity in a Phase I Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies

被引：0

作者：

Flinn, Ian W. ^{[1
]}

Byrd, John C. ^{[2
]}

Furman, Richard R. ^{[3
]}

Brown, Jennifer R. ^{[4
]}

Benson, Don M. ^{[5
]}

Coutre, Steven E. ^{[6
]}

Kahl, Brad S. ^{[7
]}

Smith, B. Douglas ^{[8
]}

Wagner-Johnston, Nina D. ^{[9
]}

Spurgeon, Stephen E. ^{[10
]}

Giese, Neill A. ^{[11
]}

Yu, Albert S. ^{[12
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA

[6] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[7] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Hematol Oncol Sect, Madison, WI USA

[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[9] Washington Univ, Sch Med, St Louis, MO USA

[10] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[11] Calistoga Pharmaceut Inc, Seattle, WA USA

[12] Calistoga Pharmaceut, Seattle, WA USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：380 / 380

页数：1

共 50 条

[1] A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies
Flinn, Ian W.
Schreeder, Marshall T.
Wagner-Johnston, Nina
Boccia, Ralph V.
Leonard, John P.
Coutre, Steven E.
Holes, Leanne M.
Peterman, Sissy
Yu, Albert S.
BLOOD, 2010, 116 (21) : 1168 - 1168
[2] CLINICAL ACTIVITY IN A PHASE 1 STUDY OF CAL-101, AN ISOFORM-SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE P110DELTA, IN PATIENTS WITH B-CELL MALIGNANCIES
Brown, J.
Byrd, J.
Furman, R.
Flinn, I.
Benson, D.
Coutre, S.
Kahl, B.
Wagner-Johnston, N.
Spurgeon, S.
Pratz, K.
Giese, N.
Yu, O. A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 466 - 466
[3] Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Kahl, Brad
Byrd, John C.
Flinn, Ian W.
Wagner-Johnston, Nina
Spurgeon, Stephen
Benson, Don M., Jr.
Furman, Richard R.
Brown, Jennifer R.
Coutre, Steven
Lannutti, Brian
Giese, Neil A.
Ulrich, Roger G.
Webb, Heather K.
Peterman, Sissy
Holes, Leanne
Yu, Albert S.
BLOOD, 2010, 116 (21) : 741 - 741
[4] CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Furman, Richard R.
Byrd, John C.
Brown, Jennifer R.
Coutre, Steven E.
Benson, Don M., Jr.
Wagner-Johnston, Nina D.
Flinn, Ian W.
Kahl, Brad S.
Spurgeon, Stephen E.
Lannutti, Brian
Giese, Neil A.
Webb, Heather K.
Ulrich, Roger G.
Peterman, Sissy
Holes, Leanne M.
Yu, Albert S.
BLOOD, 2010, 116 (21) : 31 - 31
[5] PRELIMINARY EVIDENCE OF CLINICAL ACTIVITY IN A PHASE 1 STUDY OF CAL-101, A POTENT SELECTIVE INHIBITOR OF THE P110DELTA ISOFORM OF PHOSPHATIDYLINOSITOL 3-KINASE, IN PATIENT WITH B-CELL MALIGNANCIES
Flinn, W.
Byrd, J.
Furman, R.
Brown, J.
Lin, T.
Bello, C.
Giese, N.
Yu, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 303 - 303
[6] Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.
Furman, R. R.
Byrd, J. C.
Flinn, I. W.
Coutre, S. E.
Benson, D. M., Jr.
Brown, J. R.
Kahl, B. S.
WagnerJohnston, N. D.
Giese, N. A.
Yu, A. S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[7] SIGNIFICANT CLINICAL ACTIVITY OF CAL-101, AN ISOFORM-SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3 KINASE P110D, IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT AND MANTLE CELL LYMPHOMA
Kahl, B.
Byrd, J.
Flinn, I.
Wagner-Johnston, N.
Spurgeon, S.
Benson, D.
Furman, R.
Brown, J.
Coutre, S.
Yu, A.
ANNALS OF ONCOLOGY, 2011, 22 : 199 - 199
[8] A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.
Flinn, I. W.
Schreeder, M. T.
Coutre, S. E.
Leonard, J.
Wagner-Johnston, N. D.
De Vos, S.
Boccia, R. V.
Holes, L.
Peterman, S.
Miller, L. L.
Yu, A. S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[9] Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia.
Coutre, S. E.
Byrd, J. C.
Furman, R. R.
Brown, J. R.
Benson, D. M.
Wagner-Johnston, N. D.
Flinn, I. W.
Kahl, B. S.
Spurgeon, S. E. F.
Lannutti, B. J.
Hsu, H. K. W.
Ulrich, R.
Peterman, S.
Holes, L.
Miller, L. L.
Yu, A. S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[10] Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies
Flinn, I. W.
Byrd, J. C.
Furman, R. R.
Brown, J. R.
Lin, T. S.
Bello, C.
Giese, N. A.
Yu, A. S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →